Education
About Us
Working with TipRanks
Follow Us
Kaken Pharmaceutical Co (KKPCF)
:KKPCF
Total Valuation
Kaken Pharmaceutical Co has a market cap or net worth of $941.09M. The enterprise value is $94.42B.
Market Cap$941.09M
Enterprise Value$94.42B
Share Statistics
Kaken Pharmaceutical Co has 44,139,730 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding44,139,730
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Kaken Pharmaceutical Co’s return on equity (ROE) is 0.09 and return on invested capital (ROIC) is 9.21%.
Return on Equity (ROE)0.09
Return on Assets (ROA)0.07
Return on Invested Capital (ROIC)9.21%
Return on Capital Employed (ROCE)0.13
Revenue Per Employee82.85M
Profits Per Employee12.29M
Employee Count1,135
Asset Turnover0.49
Inventory Turnover1.88
Valuation Ratios
The current PE Ratio of Kaken Pharmaceutical Co is 12.26. Kaken Pharmaceutical Co’s PEG ratio is -0.33.
PE Ratio12.26
PS Ratio0.00
PB Ratio0.95
Price to Fair Value1.12
Price to FCF0.00
Price to Operating Cash Flow0.00
PEG Ratio-0.33
Income Statement
In the last 12 months, Kaken Pharmaceutical Co had revenue of 94.03B and earned 13.95B in profits. Earnings per share was 365.42.
Revenue94.03B
Gross Profit58.26B
Operating Income21.04B
Pretax Income19.43B
Net Income13.95B
EBITDA22.02B
Earnings Per Share (EPS)365.42
Cash Flow
In the last 12 months, operating cash flow was 0.00 and capital expenditures 0.00, giving a free cash flow of 0.00 billion.
Operating Cash Flow0.00
Free Cash Flow0.00
Free Cash Flow per Share0.00
Dividends & Yields
Kaken Pharmaceutical Co pays an annual dividend of $0.522, resulting in a dividend yield of 4.73%
Dividend Per Share$0.522
Dividend Yield4.73%
Payout Ratio20.52%
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.25
52-Week Price Change12.52%
50-Day Moving Average27.75
200-Day Moving Average27.54
Relative Strength Index (RSI)46.72
Average Volume (3m)6.00
Important Dates
Kaken Pharmaceutical Co upcoming earnings date is Jul 31, 2025, TBA Not Confirmed.
Last Earnings DateMay 12, 2025
Next Earnings DateJul 31, 2025
Ex-Dividend DateMar 28, 2025
Financial Position
Kaken Pharmaceutical Co as a current ratio of 3.67, with Debt / Equity ratio of 2.52%
Current Ratio3.67
Quick Ratio3.04
Debt to Market Cap0.02
Net Debt to EBITDA-2.28
Interest Coverage Ratio751.29
Taxes
In the past 12 months, Kaken Pharmaceutical Co has paid 5.49B in taxes.
Income Tax5.49B
Effective Tax Rate0.28
Enterprise Valuation
Kaken Pharmaceutical Co EV to EBITDA ratio is 5.48, with an EV/FCF ratio of 4.71.
EV to Sales1.28
EV to EBITDA5.48
EV to Free Cash Flow4.71
EV to Operating Cash Flow4.06
Balance Sheet
Kaken Pharmaceutical Co has $79.75B in cash and marketable securities with ¥3.85B in debt, giving a net cash position of -$75.90B billion.
Cash & Marketable Securities$79.75B
Total Debt¥3.85B
Net Cash-$75.90B
Net Cash Per Share-$1.72K
Tangible Book Value Per Share$3.49K
Margins
Gross margin is 61.96%, with operating margin of 22.37%, and net profit margin of 14.83%.
Gross Margin61.96%
Operating Margin22.37%
Pretax Margin20.67%
Net Profit Margin14.83%
EBITDA Margin23.42%
EBIT Margin20.70%
Analyst Forecast
The average price target for Kaken Pharmaceutical Co is $38.66, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$38.66
Price Target Upside44.79% Upside
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast―
EPS Growth Forecast―